UNIQURE NV (QURE)
NL0010696654 - Common Stock
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
LEXINGTON, Mass. and AMSTERDAM, Nov. 21, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative...
uniQure Breaks Below 200-Day Moving Average - Notable for QURE
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a potential expedited clinical development pathway...
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS
LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative...
uniQure is Now Oversold (QURE)
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
LEXINGTON, Mass. and AMSTERDAM, Sept. 23, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative...
Relative Strength Alert For uniQure
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative...
QURE Stock Earnings: uniQure Beats EPS, Beats Revenue for Q2 2024
QURE stock results show that uniQure beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
QURE Stock Earnings: uniQure Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips uniQure (NASDAQ:QURE) just reported results for the second quarter of 2024.uniQ...
uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update
uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update
~ Announced RMAT designation for AMT-130 in Huntington’s disease and positive interim Phase I/II data demonstrating the slowing of disease progression and...
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene therapy candidates ~ ~ Immediate...
Tuesday Sector Leaders: Manufacturing, Drugs
MULN Stock Alert: Mullen Announces EV Sale to Spencer Manufacturing
Mullen stock is down on Tuesday even as MULN shareholders learn of a new EV order for subsidiary Bollinger Motors from Spencer Manufacturing.
Why Is uniQure (QURE) Stock Up 51% Today?
UniQure stock is up on Tuesday as QURE investors react to positive clinical trial data for its Huntington’s Disease treatment candidate.
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
~ Achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit; Patients receiving high-dose AMT-130 showed...
uniQure N.V. is Now Oversold (QURE)
uniQure Announces Sale of Commercial Manufacturing Facility to Genezen
Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA
/PRNewswire/ -- Genezen, a best-in-class gene therapy CDMO, today announced an agreement to acquire uniQure's (Nasdaq: QURE) commercial gene therapy operations...
uniQure Announces Sale of Commercial Manufacturing Facility to Genezen
~ Proposed divestiture streamlines uniQure’s focus and represents an important milestone in its ongoing effort to significantly reduce operating expenses ~...
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to...